Armata Pharmaceuticals Corporate Presentation 2024

Armata Pharmaceuticals is developing bacteriophage-based therapies to treat bacterial infections and address antibiotic resistance. The presentation covers the company's clinical development programs, including lead candidates AP-PA02 and AP-SA02, partnerships with the Cystic Fibrosis Foundation and U.S. Department of Defense, and regulatory strategy for advancing phage-based therapeutics.